Keymed Bio Secures $45M Payment as AstraZeneca Starts Phase III Cancer Trial

Edgen Stock·Mar 10 2026, 09:31

Share to

Share to

Copy link

Key Takeaways

Keymed Bio received a $45 million milestone payment from its partner AstraZeneca, a significant financial and clinical validation for its cancer drug candidate CMG901. The payment confirms the asset's progression into a pivotal late-stage trial, boosting investor confidence and strengthening the company's financial position.

Milestone Payment: Keymed Bio has received a $45 million payment from AstraZeneca as part of their existing licensing agreement.
Clinical Advancement: The payment was triggered by the first patient being dosed in the Phase III clinical trial (CLARITY-Gastric 02) for the cancer drug sonesitatug vedotin (CMG901).
Financial Impact: The infusion of non-dilutive capital de-risks the drug's development and validates its clinical pathway, reflected in a 7.045% rise in Keymed Bio's stock.

Phase III Trial Start Triggers $45M Milestone Payment

Keymed Bio (02162.HK) announced it has received a $45 million milestone payment from AstraZeneca. The payment was a condition of the licensing agreement for sonesitatug vedotin (CMG901), an antibody-drug conjugate targeting Claudin 18.2. The trigger for the payment was the dosing of the first patient in a pivotal Phase III clinical trial, marking a critical step forward in the drug's development. This influx of capital strengthens Keymed Bio's balance sheet without diluting shareholder equity.

CMG901 Advances in Study for Advanced Gastric Cancers

The drug, also known as AZD0901, has entered a multi-center, randomized, controlled Phase III study named CLARITY-Gastric 02. The trial is evaluating the drug's efficacy as a first-line treatment for patients with Claudin 18.2-positive and HER2-negative advanced or metastatic gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma. For AstraZeneca, successfully initiating this trial represents a key advancement in its global oncology pipeline and its strategic bet on CMG901's potential in a hard-to-treat patient population.

Payment Boosts Investor Confidence as Stock Gains 7%

This clinical and financial milestone provides tangible validation for Keymed Bio's platform and its partnership strategy. Securing significant non-dilutive funding at this stage de-risks the asset and reinforces investor confidence in the drug's path to potential commercialization. The market reacted positively to the news, with Keymed Bio's stock price increasing by 7.045%. The event underscores the value embedded in the company's clinical pipeline and its ability to execute on strategic collaborations.